TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate efficacy and safety of TachoSil® in cardiovascular surgery

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Cohort Study of TachoSil (TC-018-IN)

NCT00285623

Blood Loss, Surgical

COMPLETED

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

NCT01500135

Bleeding

COMPLETED PHASE3

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

NCT06664775

Hemorrhage

RECRUITING PHASE3

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

NCT01192022

Hemorrhage

COMPLETED PHASE3

Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)

NCT00546169

Hemorrhage

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haemorrhage Haemostasis Cardiovascular Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TachoSil®

Group Type ACTIVE_COMPARATOR

fibrinogen (human) + thrombin (human)

Intervention Type DRUG

Standard Treatment

Standard Treatment of haemorrhage in cardiovascular surgery

Group Type ACTIVE_COMPARATOR

Standard haemostatic treatment in cardiovascular surgery

Intervention Type DRUG

Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fibrinogen (human) + thrombin (human)

Intervention Type DRUG

Standard haemostatic treatment in cardiovascular surgery

Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

At Screening:

1. Has the subject given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the subject. In this trial the screening is the first trial related activity.
2. For female subjects of childbearing potential: Is the pregnancy test at screening negative?
3. Does the female subject of childbearing potential use adequate contraception (contraceptive pill, contraceptive injection, contraceptive implant or intrauterine device)?
4. Is the subject ≥ 18 years of age?
5. Is the following planned: An elective surgery on the heart, the ascending aorta or arch, requiring cardiopulmonary bypass procedure?

Intra operative (after primary haemostatic treatment):
6. Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed that requires supportive haemostatic treatment present?
7. Has the area with the most problematic haemorrhage (target area) been identified? (please note that this must be done before randomisation).
8. Is it possible to compress the randomised treatment (TachoSil® or control fleece material) for 3 minutes?

Exclusion Criteria

At Screening:

1. Has the subject participated in any other trial with an investigational drug or device within 30 days before inclusion in this trial?
2. Does the subject participate in a clinical trial concomitantly with the present trial?
3. Is the subject undergoing an emergency operation?
4. Has the subject a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?
5. Is the subject suffering from known coagulopathy?
6. Is the subject currently participating or has the subject previously participated in the TC-023-IM trial?
7. Is the female subject pregnant or breast feeding?

Intra operative (after primary haemostatic treatment):
8. Has liquid fibrin sealant/glue or TachoSil® been applied?
9. Has the following occurred: Disseminated intravascular coagulation (DIC), i.e. micro vascular bleeding?

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No